Up-regulation and worse prognostic marker of cytoplasmic TARBP2 expression in obstinate breast cancer

Medical Oncology

Volumn 31, Issue 4, 2014, Pages

  Xie, Xiaoming ^a   Lin, Xiaoti ^a,b   Wu, Minqing ^a   Liu, Peng ^a   Wei, Fengqin ^c   Li, Laisheng ^d   Tang, Hailin ^a   Xie, Xinhua ^a   Liu, Xiaoping ^a   Yang, Lu ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b FUJIAN PROVINCIAL TUMOR HOSPITAL   (China)

^c FUJIAN UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^d THE FIRST AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

Author keywords

Breast cancer; Prognostic factor; TARBP2; Tumor promotor

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; MOLECULAR MARKER; PROGESTERONE RECEPTOR; PROTEIN P53; RNA BINDING PROTEIN; TRANSACTIVATION RESPONSIVE RNA BINDING PROTEIN 2; UNCLASSIFIED DRUG; TRANS ACTIVATION RESPONSIVE RNA BINDING PROTEIN; TRANS-ACTIVATION RESPONSIVE RNA-BINDING PROTEIN;

ADULT; ADVANCED CANCER; ARTICLE; BREAST; BREAST CANCER; BREAST CARCINOMA; CANCER GRADING; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CELL NUCLEUS; COHORT ANALYSIS; CONTROLLED STUDY; CYTOPLASM; DISEASE FREE SURVIVAL; DISTANT METASTASIS; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; STATISTICAL SIGNIFICANCE; TISSUE MICROARRAY; TRIPLE NEGATIVE BREAST CANCER; TUMOR VOLUME; UPREGULATION; WESTERN BLOTTING; BREAST TUMOR; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MIDDLE AGED; MORTALITY; PROGNOSIS; PROMOTER REGION; TREATMENT OUTCOME; TUMOR CELL LINE;

BREAST NEOPLASMS; CELL LINE, TUMOR; CYTOPLASM; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; PROGNOSIS; PROMOTER REGIONS, GENETIC; RNA-BINDING PROTEINS; TREATMENT OUTCOME; TRIPLE NEGATIVE BREAST NEOPLASMS; UP-REGULATION;

EID: 84899102633     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-014-0868-9     Document Type: Article

References (48)

1. Siegel R, DeSantis C, Virgo K, et al. Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin. 2012;62(4):220-41.
2. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63(1):11-30.
3. Autier P, Hery C, Haukka J, et al. Advanced breast cancer and breast cancer mortality in randomized controlled trials on mammography screening. J Clin Oncol. 2009;27(35):5919-23.
4. Berry DA, Cronin KA, Plevritis SK, et al. Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med. 2005;353(17):1784-92.
5. Independent UKPoBCS. The benefits and harms of breast cancer screening: an independent review. Lancet. 2012;380(9855):1778-86.
6. Mahoney MC, Newell MS. Breast intervention: how i do it. Radiology. 2013;268(1):12-24.
7. DeSantis C, Siegel R, Bandi P, et al. Breast cancer statistics 2011. CA Cancer J Clin. 2011;61(6):409-18.
8. Lee E, McKean-Cowdin R, Ma HY, et al. Characteristics of triple-negative breast cancer in patients with a BRCA1 mutation: results from a population-based study of young women. J Clin Oncol. 2011;29(33):4373-80.
9. Abdulkarim BS, Cuartero J, Hanson J, et al. Increased risk of locoregional recurrence for women with T1-2N0 triple-negative breast cancer treated with modified radical mastectomy without adjuvant radiation therapy compared with breast-conserving therapy. J Clin Oncol. 2011;29(21):2852-8.
10. Carey LA, Dees EC, Sawyer L, et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res. 2007;13(8):2329-34.
11. Metzger O, Tutt A, de Azambuja E, et al. Dissecting the heterogeneity of triple-negative breast cancer. J Clin Oncol. 2012;30(15):1879-87.
12. Devi BC, Tang TS, Corbex M. Reducing by half the percentage of late-stage presentation for breast and cervix cancer over 4 years: a pilot study of clinical downstaging in Sarawak. Malays Ann Oncol. 2007;18(7):1172-6.
13. Gomez-Raposo C, Zambrana Tevar F, Sereno Moyano M, et al. Male breast cancer. Cancer Treat Rev. 2010;36(6):451-7.
14. Huo D, Ikpatt F, Khramtsov A, et al. Population differences in breast cancer: survey in indigenous African women reveals over-representation of triple-negative breast cancer. J Clin Oncol. 2009;27(27):4515-21.
15. Phipps AI, Chlebowski RT, Prentice R, et al. Reproductive history and oral contraceptive use in relation to risk of triple-negative breast cancer. J Natl Cancer Inst. 2011;103(6):470-7.
16. Benkirane M, Neuveut C, Chun RF, et al. Oncogenic potential of TAR RNA binding protein TRBP and its regulatory interaction with RNA-dependent protein kinase PKR. EMBO J. 1997;16(3):611-24.
17. Gatignol A, Buckler-White A, Berkhout B, et al. Characterization of a human TAR RNA-binding protein that activates the HIV-1 LTR. Science. 1991;251(5001):1597-600.
18. Gatignol A, Duarte M, Daviet L, et al. Sequential steps in Tat trans-activation of HIV-1 mediated through cellular DNA, RNA, and protein binding factors. Gene Expr. 1996;5(4-5):217-28.
19. Bai S, Nunez AL, Wei S, et al. Microsatellite instability and TARBP2 mutation study in upper urinary tract urothelial carcinoma. Am J Clin Pathol. 2013;139(6):765-70.
20. De Vito C, Riggi N, Cornaz S, et al. A TARBP2-dependent miRNA expression profile underlies cancer stem cell properties and provides candidate therapeutic reagents in Ewing sarcoma. Cancer Cell. 2012;21(6):807-21.
21. Melo SA, Ropero S, Moutinho C, et al. A TARBP2 mutation in human cancer impairs microRNA processing and DICER1 function. Nat Genet. 2009;41(3):365-70.
22. Caramuta S, Lee L, Ozata DM, et al. Clinical and functional impact of TARBP2 over-expression in adrenocortical carcinoma. Endocr Relat Cancer. 2013;20(4):551-64.
23. Melo S, Villanueva A, Moutinho C, et al. Small molecule enoxacin is a cancer-specific growth inhibitor that acts by enhancing TAR RNA-binding protein 2-mediated microRNA processing. Proc Natl Acad Sci USA. 2011;108(11):4394-9.
24. Fu X, Xue C, Huang Y, et al. The activity and expression of microRNAs in prostate cancers. Mol BioSyst. 2010;6(12):2561-72.
25. Sand M, Skrygan M, Georgas D, et al. The miRNA machinery in primary cutaneous malignant melanoma, cutaneous malignant melanoma metastases and benign melanocytic nevi. Cell Tissue Res. 2012;350(1):119-26.
26. Sand M, Skrygan M, Georgas D, et al. Expression levels of the microRNA maturing microprocessor complex component DGCR8 and the RNA-induced silencing complex (RISC) components argonaute-1, argonaute-2, PACT, TARBP1, and TARBP2 in epithelial skin cancer. Mol Carcinog. 2012;51(11):916-22.
27. Wu M, Wei W, Xiao X, et al. Expression of SIRT1 is associated with lymph node metastasis and poor prognosis in both operable triple-negative and non-triple-negative breast cancer. Med Oncol. 2012;29(5):3240-9.
28. Friedrichs K, Gluba S, Eidtmann H, et al. Overexpression of p53 and prognosis in breast cancer. Cancer. 1993;72(12):3641-7.
29. Stephan EA, Chung TH, Grant CS, et al. Adrenocortical carcinoma survival rates correlated to genomic copy number variants. Mol Cancer Ther. 2008;7(2):425-31.
30. Bannwarth S, Talakoub L, Letourneur F, et al. Organization of the human tarbp2 gene reveals two promoters that are repressed in an astrocytic cell line. J Biol Chem. 2001;276(52):48803-13.
31. Park H, Davies MV, Langland JO, et al. TAR RNA-binding protein is an inhibitor of the interferon-induced protein kinase PKR. Proc Natl Acad Sci USA. 1994;91(11):4713-7.
32. Francois C, Duverlie G, Rebouillat D, et al. Expression of hepatitis C virus proteins interferes with the antiviral action of interferon independently of PKR-mediated control of protein synthesis. J Virol. 2000;74(12):5587-96.
33. Liu H. MicroRNAs in breast cancer initiation and progression. Cell Mol Life Sci. 2012;69(21):3587-99.
34. Yu Z, Pestell RG. Small non-coding RNAs govern mammary gland tumorigenesis. J Mammary Gland Biol Neoplasia. 2012;17(1):59-64.
35. Si ML, Zhu S, Wu H, Lu Z, et al. miR-21-mediated tumor growth. Oncogene. 2007;26(19):2799-803.
36. Ma L, Reinhardt F, Pan E, et al. Therapeutic silencing of miR-10b inhibits metastasis in a mouse mammary tumor model. Nat Biotechnol. 2010;28(4):341-7.
37. Ma L, Teruya-Feldstein J, Weinberg RA. Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature. 2007;449(7163):682-8.
38. Mertens-Talcott SU, Chintharlapalli S, Li X, et al. The oncogenic microRNA-27a targets genes that regulate specificity protein transcription factors and the G2-M checkpoint in MDA-MB-231 breast cancer cells. Cancer Res. 2007;67(22):11001-11.
39. Martello G, Rosato A, Ferrari F, et al. A MicroRNA targeting dicer for metastasis control. Cell. 2010;141(7):1195-207.
40. Ibarra I, Erlich Y, Muthuswamy SK, et al. A role for microRNAs in maintenance of mouse mammary epithelial progenitor cells. Genes Dev. 2007;21(24):3238-43.
41. Lu J, Getz G, Miska EA, et al. MicroRNA expression profiles classify human cancers. Nature. 2005;435(7043):834-8.
42. Yu F, Yao H, Zhu P, et al. let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell. 2007;131(6):1109-23.
43. Lehmann U, Hasemeier B, Christgen M, et al. Epigenetic inactivation of microRNA gene hsa-mir-9-1 in human breast cancer. J Pathol. 2008;214(1):17-24.
44. Iorio MV, Ferracin M, Liu CG, et al. MicroRNA gene expression deregulation in human breast cancer. Cancer Res. 2005;65(16):7065-70.
45. Yu F, Deng H, Yao H, et al. Mir-30 reduction maintains self-renewal and inhibits apoptosis in breast tumor-initiating cells. Oncogene. 2010;29(29):4194-204.
46. Li LS, Xie XH, Luo JM, et al. Targeted expression of miR-34a using the T-VISA System suppresses breast cancer cell growth and invasion. Mol Ther. 2012;20(12):2326-34.
47. Shimono Y, Zabala M, Cho RW, et al. Downregulation of miRNA-200c links breast cancer stem cells with normal stem cells. Cell. 2009;138(3):592-603.
48. Li D, Zhao Y, Liu C, et al. Analysis of MiR-195 and MiR-497 expression, regulation and role in breast cancer. Clin Cancer Res. 2011;17(7):1722-30.